Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Supporting quality of life
The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in QuebecJournal Article
Oncologist, 27 (10), 2022.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Journal Article
Breast Cancer Res Treat, 193 (3), 2022.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Journal Article
Breast Cancer Res Treat, 193 (3), 2022.
Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative studyJournal Article
Support Care Cancer, 30 (6), 2022.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerJournal Article
Breast Cancer Res Treat, 192 (1), 2022.
Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical TrialJournal Article
Ann Surg Oncol, 29 (4), 2022.
Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, CanadaJournal Article
J Pers Med, 11 (9), 2021.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerJournal Article
Breast Cancer Res Treat, 187 (1), 2021.
DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and BloodJournal Article
Cancers (Basel), 12 (11), 2020.
Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approachJournal Article
Res Social Adm Pharm, 16 (12), 2020.